Evidence map›Paper›PMID 23835063›Full record

ArticleMolecular cancer2013

ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

Annica Wilzén, Cecilia Krona, Baldur Sveinbjörnsson, Erik Kristiansson, Daniel Dalevi, Ingrid Øra, Katleen De Preter, Raymond L Stallings, John Maris, Rogier Versteeg and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Adrenal ganglioneuroma: What you need to know.World journal of clinical cases · 2017
    Review
  9. Schwann cells: a new player in the tumor microenvironment.Cancer immunology, immunotherapy : CII · 2017
    Review
  10. Article
  11. Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

Annica WilzénDepartment of Clinical Genetics, Institution of Biomedicine, Box 413, S- 405 30, Gothenburg University, Gothenburg, Sweden. frida.abel@gu.se.
Cecilia Krona
Baldur Sveinbjörnsson
Erik Kristiansson
Daniel Dalevi
Ingrid Øra
Katleen De Preter
Raymond L Stallings
John Maris
Rogier Versteeg
Staffan Nilsson
Per Kogner
Frida Abel
Chalmers University of Technology · SEKarolinska Institutet · SEUniversity of Gothenburg · SEAcademic Medical Center · NLGhent University Hospital · BELund University · SERoyal College of Surgeons in Ireland · IEUniversity of Pennsylvania · US

Funding

MiRNA Expression in NeuroblastomaR01CA127496 · NCI · ROYAL COLLEGE OF SURGEONS IN IRELAND · PI STALLINGS, RAYMOND LOUIS · 2008 to 2012
$976k
NCI NIH HHS 5R01CA127496
6 · The paper itself

Abstract

backgroundNeuroblastoma (NB) tumours are commonly divided into three cytogenetic subgroups. However, by unsupervised principal components analysis of gene expression profiles we recently identified four distinct subgroups, r1-r4. In the current study we characterized these different subgroups in more detail, with a specific focus on the fourth divergent tumour subgroup (r4).

methodsExpression microarray data from four international studies corresponding to 148 neuroblastic tumour cases were subject to division into four expression subgroups using a previously described 6-gene signature. Differentially expressed genes between groups were identified using Significance Analysis of Microarray (SAM). Next, gene expression network modelling was performed to map signalling pathways and cellular processes representing each subgroup. Findings were validated at the protein level by immunohistochemistry and immunoblot analyses.

resultsWe identified several significantly up-regulated genes in the r4 subgroup of which the tyrosine kinase receptor ERBB3 was most prominent (fold change: 132-240). By gene set enrichment analysis (GSEA) the constructed gene network of ERBB3 (n = 38 network partners) was significantly enriched in the r4 subgroup in all four independent data sets. ERBB3 was also positively correlated to the ErbB family members EGFR and ERBB2 in all data sets, and a concurrent overexpression was seen in the r4 subgroup. Further studies of histopathology categories using a fifth data set of 110 neuroblastic tumours, showed a striking similarity between the expression profile of r4 to ganglioneuroblastoma (GNB) and ganglioneuroma (GN) tumours. In contrast, the NB histopathological subtype was dominated by mitotic regulating genes, characterizing unfavourable NB subgroups in particular. The high ErbB3 expression in GN tumour types was verified at the protein level, and showed mainly expression in the mature ganglion cells.

conclusionsConclusively, this study demonstrates the importance of performing unsupervised clustering and subtype discovery of data sets prior to analyses to avoid a mixture of tumour subtypes, which may otherwise give distorted results and lead to incorrect conclusions. The current study identifies ERBB3 as a clear-cut marker of a GNB/GN-like expression profile, and we suggest a 7-gene expression signature (including ERBB3) as a complement to histopathology analysis of neuroblastic tumours. Further studies of ErbB3 and other ErbB family members and their role in neuroblastic differentiation and pathogenesis are warranted.

Indexed as

Biomarkers, TumorGanglioneuroblastomaGanglioneuromaGene Expression Regulation, NeoplasticGene OntologyGene Regulatory NetworksHumansOligonucleotide Array Sequence AnalysisPeripheral Nervous System NeoplasmsReceptor, ErbB-3TranscriptomeUp-RegulationBiomarkers, TumorERBB3 protein, humanReceptor, ErbB-3

Identifiers

PMID23835063
PMCPMC3766266
OpenAlexW2097939095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.